# Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

> **NCT00763347** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 82 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** SYR-619
- **DRUG:** SYR-619
- **DRUG:** SYR-619
- **DRUG:** SYR-619
- **DRUG:** Placebo
- **DRUG:** Alogliptin

## Key facts

- **NCT ID:** NCT00763347
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Voluntarily terminated based on preliminary non-clinical findings.
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00763347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00763347, "Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00763347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*